Top

Published in:

01-10-2018 | Research Paper

Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma

Authors: Kotaro Matsuda, Hiroaki Miyoshi, Mayuko Moritsubo, Koji Hiraoka, Tetsuya Hamada, Naoto Shiba, Koichi Ohshima

Published in: Clinical & Experimental Metastasis | Issue 7/2018

Abstract

Autoimmune regulator (AIRE) is a transcription factor that is expressed in medullary thymic epithelial cells. It plays an essential role in central tolerance by eliminating self-reactive T cells. Recently, extrathymic AIRE-expressing cells have been revealed, which are associated with peripheral tolerance. Moreover, AIRE expression has been demonstrated in skin tumors and breast cancer. However, the expression of AIRE in osteosarcoma is unknown. We used immunohistochemistry to investigate AIRE expression in biopsy samples from 43 patients with conventional osteosarcoma and statistically analyzed the association between AIRE expression and clinicopathological characteristics. High AIRE expression was detected in 25 patients (58.1%), and significantly associated with the presence of lung metastasis (P = 0.014) and an increased number of forkhead box P3-positive tumor-infiltrating lymphocytes (regulatory T cells) (P = 0.014). The overall survival rate for all osteosarcoma patients with high AIRE expression was significantly shorter than that for those with low AIRE expression (P = 0.046). In a subgroup analysis of American Joint Committee on Cancer stage II patients who underwent complete surgical resection and conventional chemotherapy, the overall survival and metastasis-free survival rates were significantly shorter for patients with high AIRE expression than for those with low AIRE expression (P = 0.019 and P < 0.01, respectively). High AIRE expression was confirmed to be an independent poor prognostic factor for both overall survival (hazard ratio: 3.841, P = 0.038) and metastasis-free survival (hazard ratio: 4.348, P = 0.022) in the multivariate analysis. The evaluation of AIRE expression may be useful for stratifying osteosarcoma patients for more effective clinical follow-up.

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106:1154–1161CrossRefPubMed

Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR (2012) A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012:704872. https://doi.org/10.1155/2012/704872 CrossRefPubMedPubMedCentral

Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N (2009) Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastas 26:1005–1012. https://doi.org/10.1007/s10585-009-9290-7 CrossRef

Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33:3029–3035. https://doi.org/10.1200/JCO.2014.59.4895 CrossRefPubMedPubMedCentral

Mathis D, Benoist C (2009) Aire. Annu Rev Immunol 27:287–312. https://doi.org/10.1146/annurev.immunol.25.022106.141532 CrossRefPubMed

Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D (2002) Projection of an immunological self shadow within the thymus by the aire protein. Science 298:1395–1401CrossRefPubMed

Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, Krohn KJ, Lalioti MD, Mullis PE, Antonarakis SE, Kawasaki K, Asakawa S, Ito F, Shimizu N (1997) Positional cloning of the APECED gene. Nat Genet 17:393–398CrossRefPubMed

Eldershaw SA, Sansom DM, Narendran P (2011) Expression and function of the autoimmune regulator (Aire) gene in non-thymic tissue. Clin Exp Immunol 163:296–308. https://doi.org/10.1111/j.1365-2249.2010.04316.x CrossRefPubMedPubMedCentral

Gardner JM, Metzger TC, McMahon EJ, Au-Yeung BB, Krawisz AK, Lu W, Price JD, Johannes KP, Satpathy AT, Murphy KM, Tarbell KV, Weiss A, Anderson MS (2013) Extrathymic Aire-expressing cells are a distinct bone marrow-derived population that induce functional inactivation of CD4⁺ T cells. Immunity 39:560–572. https://doi.org/10.1016/j.immuni.2013.08.005 CrossRefPubMedPubMedCentral

10.

Hobbs RP, DePianto DJ, Jacob JT, Han MC, Chung BM, Batazzi AS, Poll BG, Guo Y, Han J, Ong S, Zheng W, Taube JM, Čiháková D, Wan F, Coulombe PA (2015) Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. Nat Genet 47:933–938. https://doi.org/10.1038/ng.3355 CrossRefPubMedPubMedCentral

11.

Bianchi F, Sommariva M, De Cecco L, Triulzi T, Romero-Cordoba S, Tagliabue E, Sfondrini L, Balsari A (2016) Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. Cell Cycle 15:3220–3229CrossRefPubMedPubMedCentral

12.

Rosenberg AE, Cleton-Jansen AM, de Pinieux G, Deyrup AT, Hauben E, Squire J (2013) Conventional osteosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F (eds) WHO Classification of Tumors of Soft Tissue and Bone, 4th edn. IARC, Lyon, pp 282–288

13.

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061CrossRefPubMed

14.

Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA (2013) Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339:1219–1224. https://doi.org/10.1126/science.1233913 CrossRefPubMedPubMedCentral

15.

Lei Y, Ripen AM, Ishimaru N, Ohigashi I, Nagasawa T, Jeker LT, Bösl MR, Holländer GA, Hayashi Y, Malefyt Rde W, Nitta T, Takahama Y (2011) Aire-dependent production of XCL1 mediates medullary accumulation of thymic dendritic cells and contributes to regulatory T cell development. J Exp Med 208:383–394. https://doi.org/10.1084/jem.20102327 CrossRefPubMedPubMedCentral

16.

Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS (2008) Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321:843–847. https://doi.org/10.1126/science.1159407 CrossRefPubMedPubMedCentral

17.

Poliani PL, Kisand K, Marrella V, Ravanini M, Notarangelo LD, Villa A, Peterson P, Facchetti F (2010) Human peripheral lymphoid tissues contain autoimmune regulator-expressing dendritic cells. Am J Pathol 176:1104–1112. https://doi.org/10.2353/ajpath.2010.090956 CrossRefPubMedPubMedCentral

18.

Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154CrossRefPubMedPubMedCentral

19.

Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18:6110–6121. https://doi.org/10.1158/1078-0432.CCR-12-2130 CrossRefPubMedPubMedCentral

20.

Abramson J, Giraud M, Benoist C, Mathis D (2010) Aire’s partners in the molecular control of immunological tolerance. Cell 140:123–135. https://doi.org/10.1016/j.cell.2009.12.030 CrossRefPubMed

21.

Guerau-de-Arellano M, Mathis D, Benoist C (2008) Transcriptional impact of Aire varies with cell type. Proc Natl Acad Sci USA 105:14011–14016. https://doi.org/10.1073/pnas.0806616105 CrossRefPubMedPubMedCentral

22.

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H, Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed

Title: Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma
Authors: Kotaro Matsuda
Hiroaki Miyoshi
Mayuko Moritsubo
Koji Hiraoka
Tetsuya Hamada
Naoto Shiba
Koichi Ohshima
Publication date: 01-10-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9928-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2018

The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies

Short-course regimen of palliative radiotherapy in complicated bone metastases: a phase i–ii study (SHARON Project)

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment

The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer

Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer